<DOC>
	<DOCNO>NCT00146549</DOCNO>
	<brief_summary>The purpose study compare two different combination chemotherapy trastuzumab initial treatment HER2 positive advance breast cancer . Half patient receive trastuzumab combination taxane form chemotherapy ( either paclitaxel docetaxel ) , group receive trastuzumab combination vinorelbine .</brief_summary>
	<brief_title>Trastuzumab Combination With Vinorelbine Taxane-Based Chemotherapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>- All patient receive trastuzumab randomize one two arm . Arm A : Trastuzumab combination weekly vinorelbine Arm B : Trastuzumab combination weekly taxane-based regimen , either paclitaxel docetaxel , choose discretion investigator . - Treatment administered outpatient basis . Trastuzumab administer weekly . There one-time loading dose first week first cycle . For initial treatment , , trastuzumab dose 4mg/kg . The dose subsequent weekly trastuzumab treatment 2mg/kg . - Arm A : vinorelbine administer every week dose adjust base absolute neutrophil count week . Vinorelbine give trastuzumab . - Arm B : Either paclitaxel give weekly ( dose base absolute neutrophil count ) docetaxel give week 1,2,3,5,6,7 8-week cycle ( dose base upon absolute neutrophil count ) . Patients paclitaxel also receive dexamethasone , diphenhydramine ranitidine help prevent allergic hypersensitivity reaction . Patients docetaxel receive dexamethasone help reduce fluid retention edema . - Every 8 week patient cancer re-evaluated see treatment work . If treatment appear work , treatment continue . Standard radiological testing ( x-rays , CT scan , radioactive drug scan , MRI 's ) use follow disease treatment . - Heart function measure 16 week sure safe continue treatment . - Every 8 week , patient ' ask complete brief write survey ask symptoms side effect . - Patients ' remain treatment long disease progression unacceptable side effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast cancer , stage IV disease Tumors must HER2 overexpressing Measurable disease , define least one lesion accurately measure least one dimension 18 year age old Life expectancy great 6 month ECOG performance status 02 ANC count &gt; 1,500/mm3 Platelets &gt; 100,000/mm3 Total bilirubin &lt; 1.5 mg/dl AST/ALT &lt; 115 U/I Creatinine &lt; 2.0 mg/dl Glucose &lt; 200 mg/dl LVEF &gt; 50 % Prior chemotherapy prior trastuzumab therapy metastatic breast cancer Concurrent hormonal therapy , chemotherapy , radiation treatment Pregnant lactating woman Known brain metastasis leptomeningeal carcinomatosis History grade 3 4 allergic reaction attribute compound similar chemical biologic composition agent study Preexisting neuropathy cause excess grade 1 Uncontrolled intercurrent illness History nonbreast cancer malignancy except carcinoma situ cervix nonmelanoma skin cancer Patients take macrolide antibiotic , ketoconazole , AZT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>HER2-positive Breast cancer</keyword>
	<keyword>HER2 overexpressing</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Taxotere</keyword>
	<keyword>taxol</keyword>
</DOC>